Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mission Pharmacal for women and babies

This article was originally published in The Tan Sheet

Executive Summary

The San Antonio-based firm extends its products marketed to women into OTC lotions with the acquisition of Dr. Smith's Diaper Ointment from innovator Esrubar and marketer Beta Dermaceuticals. Mission Pharmacal did not disclose financial terms of the Aug. 31 deal, which also includes Rash-n-All Ointment. The firm already markets CitraNatal prenatal vitamins and Ferralet 90 iron therapy Rx products, and will give samples of Dr. Smith's products to health care providers who buy its prescription drugs and can recommend the ointment to patients, said company President Neill Walsdorf, Jr. According to Information Resources Inc., Dr. Smith's sales were $1.85 million, or 1.82 percent of the category, in the 52 weeks ending Aug. 9, excluding sales at Wal-Mart, club stores and convenience stores. Desitin leads the baby ointment category at $15.7 million, or 15.37 percent, Chicago-based IRI data show. Mission Pharmacal expects to extend Dr. Smith's Diaper Ointment nationwide in 2010 before growing Rash-n-All sales

You may also be interested in...



US High Court Punts On ‘Objective Falsity’ FCA Standard

Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.

EU Launches ‘Structured Dialog’ To Thrash Out Supply Chain Concerns

The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.

Samsung Bioepis Pushes Stelara Rival Into Phase I

Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase I trials.

Topics

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel